Core Insights - MiMedx Group, Inc. celebrates the 15th anniversary of its flagship products, EPIFIX and AMNIOFIX, which are placental allografts used in wound care and surgical recovery settings [1][2] Company Overview - MiMedx is recognized as a pioneer and leader in providing healing solutions, focusing on chronic and hard-to-heal wounds with a diverse product portfolio for wound care, burn, and surgical applications [3] - The company's vision is to become the leading global provider of healing solutions through continuous innovation aimed at restoring quality of life [3] Product Impact - EPIFIX and AMNIOFIX have been instrumental in changing the paradigm of wound care treatment and surgical recovery, becoming the preferred choice across various surgical specialties due to their utility and handling characteristics [2] - The products have been extensively studied, appearing in nearly 100 clinical and scientific publications, including seven randomized controlled trials, making them the most studied placental allografts in the industry [2]